News

In The News ADVI’s Lindsay Bealor Greenleaf caught up with BioWorld to discuss drug prices and how recent proposals would impact patient access to new cures and treatments.
In The News ADVI’s Lindsay Bealor Greenleaf caught up with FierceHealthcare to discuss the latest drug pricing proposal from Speaker Pelosi and the outlook on compromise with both Senate HELP and Finance committee efforts
In The News ADVI Director Lindsay Bealor Greenleaf discussed House Democrats’ drug pricing proposal with Pink Sheet
In The News ADVI’s Lindsay Bealor Greenleaf spoke with FierceHealthcare about competition in the pharmacy space and what CVS’ presence signals for others entering the market
In The News ADVI’s Lindsay Bealor Greenleaf shared her thoughts on the implications of drug importation and the administration’s evolving policies with Bloomberg Law
In The News In her conversation with BioWorld, ADVI’s Lindsay Bealor Greenleaf shared her thoughts on the White House’s decision to withdraw the rebate rule, the impacts of the IPI model, and the role of pharmacy benefit managers in the drug supply chain
In The News ADVI’s Lindsay Bealor Greenleaf discussed the White House’s decision to withdraw the anticipated rebate rule aimed at reforming the drug supply chain and lowering prescription out-of-pocket costs
In The News ADVI’s Lindsay Bealor Greenleaf talks to the Daily Caller about the court blocking Trump’s drug price disclosure requirement for TV ads
In The News ADVI Director, Lindsay Bealor Greenleaf, discussed why including a drug’s list price in direct-to-consumer ads can be misleading to patients with The Daily Caller